CN108354938A - Janus激酶(jak)抑制剂的给药方案 - Google Patents

Janus激酶(jak)抑制剂的给药方案 Download PDF

Info

Publication number
CN108354938A
CN108354938A CN201810369706.3A CN201810369706A CN108354938A CN 108354938 A CN108354938 A CN 108354938A CN 201810369706 A CN201810369706 A CN 201810369706A CN 108354938 A CN108354938 A CN 108354938A
Authority
CN
China
Prior art keywords
therapeutically effective
atopic dermatitis
dose
administration
effective dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810369706.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·J·冈萨雷斯
S·B·科斯格罗夫
P·B·马尔帕斯
M·R·斯特格曼
W·T·科勒德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis LLC
Zoetis Services LLC
Original Assignee
Zoetis LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN108354938(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis LLC filed Critical Zoetis LLC
Publication of CN108354938A publication Critical patent/CN108354938A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201810369706.3A 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案 Pending CN108354938A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US61/674,289 2012-07-20
US201361815803P 2013-04-25 2013-04-25
US61/815,803 2013-04-25
CN201380038563.3A CN104470525A (zh) 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380038563.3A Division CN104470525A (zh) 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案

Publications (1)

Publication Number Publication Date
CN108354938A true CN108354938A (zh) 2018-08-03

Family

ID=48901189

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810369706.3A Pending CN108354938A (zh) 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案
CN201380038563.3A Pending CN104470525A (zh) 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380038563.3A Pending CN104470525A (zh) 2012-07-20 2013-07-18 Janus激酶(jak)抑制剂的给药方案

Country Status (25)

Country Link
US (1) US9522151B2 (cg-RX-API-DMAC7.html)
EP (1) EP2874630B1 (cg-RX-API-DMAC7.html)
JP (2) JP6022063B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170034949A (cg-RX-API-DMAC7.html)
CN (2) CN108354938A (cg-RX-API-DMAC7.html)
AU (1) AU2013292547B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015000808A2 (cg-RX-API-DMAC7.html)
CA (1) CA2878867C (cg-RX-API-DMAC7.html)
CY (1) CY1121436T1 (cg-RX-API-DMAC7.html)
DK (1) DK2874630T3 (cg-RX-API-DMAC7.html)
ES (1) ES2707627T3 (cg-RX-API-DMAC7.html)
HK (2) HK1209314A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20182088T1 (cg-RX-API-DMAC7.html)
HU (1) HUE042771T2 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN00370A (cg-RX-API-DMAC7.html)
LT (1) LT2874630T (cg-RX-API-DMAC7.html)
MX (1) MX360857B (cg-RX-API-DMAC7.html)
NZ (1) NZ703152A (cg-RX-API-DMAC7.html)
PL (1) PL2874630T3 (cg-RX-API-DMAC7.html)
PT (1) PT2874630T (cg-RX-API-DMAC7.html)
RS (1) RS58242B1 (cg-RX-API-DMAC7.html)
SI (1) SI2874630T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900044T1 (cg-RX-API-DMAC7.html)
WO (1) WO2014015107A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500134B (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027879B1 (ru) 2013-02-22 2017-09-29 Пфайзер Инк. ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
CN116270646A (zh) 2015-10-16 2023-06-23 艾伯维公司 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10973913B2 (en) 2016-02-16 2021-04-13 Washington University JAK inhibitors and uses thereof
CN107098908B (zh) 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2022133420A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
CA3303899A1 (en) * 2021-03-16 2026-05-13 Hk Inno.N Corporation Novel salts of heterocyclic compound as protein kinase inhibitor and uses thereof
AU2022263067A1 (en) * 2021-04-22 2023-11-02 Shenzhen Chipscreen Biosciences Co., Ltd. Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020905A1 (en) * 2008-08-20 2010-02-25 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds

Also Published As

Publication number Publication date
WO2014015107A1 (en) 2014-01-23
ES2707627T3 (es) 2019-04-04
MX2015000871A (es) 2015-05-07
BR112015000808A2 (pt) 2017-06-27
CN104470525A (zh) 2015-03-25
HRP20182088T1 (hr) 2019-02-08
RS58242B1 (sr) 2019-03-29
HK1252083A1 (zh) 2019-05-17
HK1209314A1 (en) 2016-04-01
EP2874630B1 (en) 2018-12-05
JP6022063B2 (ja) 2016-11-09
KR20170034949A (ko) 2017-03-29
IN2015DN00370A (cg-RX-API-DMAC7.html) 2015-06-12
CA2878867C (en) 2018-01-09
SMT201900044T1 (it) 2019-02-28
CY1121436T1 (el) 2020-05-29
PT2874630T (pt) 2019-01-31
LT2874630T (lt) 2019-02-11
US20150126535A1 (en) 2015-05-07
EP2874630A1 (en) 2015-05-27
AU2013292547A1 (en) 2015-01-22
SI2874630T1 (sl) 2019-04-30
KR20150028299A (ko) 2015-03-13
JP2017019816A (ja) 2017-01-26
NZ703152A (en) 2016-03-31
US9522151B2 (en) 2016-12-20
CA2878867A1 (en) 2014-01-23
HUE042771T2 (hu) 2019-07-29
PL2874630T3 (pl) 2019-04-30
JP2015522620A (ja) 2015-08-06
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
DK2874630T3 (en) 2019-01-28
MX360857B (es) 2018-11-20

Similar Documents

Publication Publication Date Title
CA2878867C (en) Dosing regimen for janus kinase (jak) inhibitors
US20240390378A1 (en) Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp)
US12569487B2 (en) Treatment of hidradenitis with jak inhibitors
US12622912B2 (en) Application of pyrido[1,2-a]pyrimidinone analog
EP4333840B1 (en) Jak1 pathway inhibitors for the treatment of prurigo nodularis
CN118984704A (zh) 治疗卵巢癌的药物组合和方法
CN118541364A (zh) 氨基吡唑化合物的用途
US20230293544A1 (en) Methods, dosage regimens, and compositions for treating hidradenitis
CN116744923A (zh) 普利多匹定及类似物用于治疗rett综合征的用途
HK40115079A (en) Methods, dosage regimens, and compositions for treating hidradenitis
TW202302110A (zh) 包含jak3/jak1/tbk1選擇性抑制劑的藥物組合物及其醫藥用途

Legal Events

Date Code Title Description
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1252083

Country of ref document: HK